Skip to content

Search

Community collaboration ensures ending RHD is everybody’s business

Collaboration is the driving force behind ‘END RHD Demonstration Communities’ – a new community-driven, research-backed approach to tackling rheumatic heart disease (RHD) in remote Australia.

Annual CRE Investigators' Meeting draws researchers from around the world

Between 3rd - 5th May 2018, researchers from Australia, New Zealand, South Africa, and the United States (representing their Uganda collaboration) convened in Fremantle, Western Australia to attend the Strep A Spectrum Meetings: from Science to Strategy.

$2 million grant to develop diagnostic tool for rheumatic fever

The Kids Research Institute Australia & Menzies School of Health Research will lead an international project to develop a diagnostic tool for acute rheumatic fever.

For kids, by kids: New “Boom Boom” song teaches children how to prevent deadly heart disease

Once you hear it, you won’t be able to get it out of your head – and that’s exactly the point of the new song ‘Boom Boom’.

Standardization of Epidemiological Surveillance of Acute Rheumatic Fever

Acute rheumatic fever (ARF) is a multiorgan inflammatory disorder that results from the body's autoimmune response to pharyngitis or a skin infection caused by Streptococcus pyogenes (Strep A). Acute rheumatic fever mainly affects those in low- and middle-income nations, as well as in indigenous populations in wealthy nations, where initial Strep A infections may go undetected.

Harmonizing Surveillance Methodologies for Group A Streptococcal Diseases

Group A Streptococcus (Strep A) is responsible for a significant global health and economic burden. The recent prioritization of Strep A vaccine development by the World Health Organization has prompted global research activities and collaborations. To progress this prioritization, establishment of robust surveillance for Strep A to generate updated regional disease burden estimates and to establish platforms for future impact evaluation is essential.